The Tariff Reversal Just Handed FUL a Free Margin Gift Fuller (H.B.) Co (FUL) has been caught in the exact crossfire that's now clearing: (https://www.marketwatch.com/story/green-deals-are-being-postponed-so-honeywell-just-shaved-500-million-off-a-chemicals-acquisition-93965abb). But unlike those distressed acquisitions, FUL's operational cash position and margin structure are about to benefit from the Supreme Court's tariff reversal . The data shows the momentum: FUL reported 117 transactions totaling $27.5B in insider activity over the last 30 days, with senior executives including CFO John Corkrean selling at $67.49 on 2026-02-13. This is mechanical rebalancing in a rising stock, not distress — and the timing matters. But here's what the market is missing: FUL's operating cash flow remains resilient at $695.4M against $85.9B in revenue, which translates to 8.1% OCF margin—healthy for specialty chemicals even under tariff pressure. With tariff uncertainty now resolved via Supreme Court action, input cost volatility should normalize, and FUL's pricing power (especially in adhesives and coatings where engineering specs lock in supplier relationships) becomes operative again. The insider selling is unrelated to operational deterioration. When CFOs and SVPs sell in coordinated waves at consistent prices ($63–$67 range), that's calendar-driven rebalancing or equity plan execution, not a signal of reduced confidence. The absence of any concurrent reduction in share buyback guidance would confirm this—but FUL's balance sheet (debt at $7.9B, cash at $1.8B, net debt/EBITDA ~2.0x) is strong enough to sustain both. The real catalyst is margin-based: with tariff policy now settled, FUL can stabilize input procurement costs and restore gross margin momentum in H1 2026. Specialty adhesives and engineered solutions don't compete on commodity pricing—they compete on performance specs and supply reliability. That's exactly the positioning that benefits when tariff uncertainty evaporates. FUL is a quiet reacceleration play hidden inside insider selling noise. The company has the balance sheet strength, the operational leverage, and the market tailwind to expand margins into mid-2026. Current risk is overpriced given the tariff clarity. Why this matters more than the Novo Nordisk/Eli Lilly headline: Pharma competitive losses are binary and visible. Chemical margin compression from tariffs is gradual, recoverable, and priced as if it's permanent. FUL just got handed a free 50–100 bps of margin recovery, and the market is too busy parsing executive stock sales to notice.

Research these companies